ton, and Alan R. Zinsmeister. Effects of a -opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 284: G558-G566, 2003; 10.1152 10. /ajpgi.00360.2002pare the effects of the -opioid agonist asimadoline and placebo on visceral sensation and gastrointestinal (GI) motor functions in humans, 91 healthy participants were randomized in a double-blind fashion to 0.15, 0.5, or 1.5 mg of asimadoline or placebo orally twice a day for 9 days. We assessed satiation (nutrient drink test), colonic compliance, tone, perception of colonic distension (barostat), and whole gut transit (scintigraphy). Treatment effect was assessed by analysis of covariance. Asimadoline increased nutrient drink intake (P ϭ 0.03). Asimadoline decreased colonic tone during fasting (P ϭ 0.03) without affecting postprandial colonic contraction, compliance, or transit. Gas scores in response to colonic distension were decreased with 0.5 mg of asimadoline at low levels (8 mmHg above operating pressure) of distension (P ϭ 0.04) but not at higher levels of distension. Asimadoline at 1.5 mg increased gas scores at 16 mmHg of distension (P ϭ 0.03) and pain scores at distensions of 8 and 16 mmHg (P ϭ 0.003 and 0.03, respectively) but not at higher levels of distension. Further studies of this compound in diseases with altered satiation or visceral sensation are warranted. sensation; visceral; stomach; colon; barostat VISCERAL PAIN AND DISCOMFORT are relevant clinical features of many medical processes, including functional gastrointestinal (GI) disorders (57). These are frequent and chronic-relapsing conditions with a great impact on quality of life (23), yet no satisfactory treatment is available for treatment of pain in these highly prevalent conditions.The three major opioid receptors, , ␦, and , are distributed in the peripheral and central nervous systems (45, 53) and are known to modulate visceral nociception (16,22,29).